Therapeutic Response
HER2-negative, PIK3CA somatic variants, and PR positive
status confers therapeutic sensitivity to
Fulvestrant
in combination with
Inavolisib and
Palbociclib
in patients with
Invasive Breast Carcinoma.
Statements
| Source and description |
Itovebi (inavolisib) [product monograph]. HC.
Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.
|
Itovebi (inavolisib) [package insert]. FDA.
The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.
|